Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.

Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification from Bank of America Corporation on August 19, 2026. The notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 10% of Lakefront’ voting rights on August 18, 2026, following the acquisition of Lakefront voting rights and equivalent financial instruments.

On August 19, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 1,419,144 voting rights and 5,243,453 equivalent financial instruments, representing together 10.11% of Lakefront’ currently outstanding 65,897,071 shares.

Summary of the transactions:

Date on which the threshold was crossed

Date of notification

Direct voting rights after the transaction

Equivalent financial instruments after the transaction

Total (%) voting rights

August 18, 2026

August 19, 2026

2.15%

7.96%

10.11%

Content of the notification from Bank of America Corporation:

The notification dated August 19, 2026, contains the following information: • Date of notification: August 19, 2026 • Date on which the threshold is crossed: August 18, 2026 • Threshold of voting rights crossed (in %): 10% • Notification by: Bank of America Corporation • Denominator: 65,897,071 • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities • Notified details:

A) Voting Rights

Previous notification

After the transaction

# of voting rights

# of voting rights

% of voting rights

Holder of voting rights

Linked to securities

Not linked to securities

Linked to securities

Not linked to securities

Bank of America Corporation

0

0

0.00%

Bank of America, National Association

14,348

10,701

0.02%

Merrill Lynch International

8,234

0

0.00%

BofA Securities, Inc.

600,314

1,407,905

2.14%

Merrill Lynch, Pierce, Fenner & Smith Incorporated

462

462

0.00%

U.S. Trust Company of Delaware

76

76

0.00%

Subtotal

623,434

1,419,144

2.15%

TOTAL

1,419,144

0

2.15%

0.00%

B) Equivalent financial instruments

After the transaction

Holder of equivalent financial instruments

Type of financial instrument

Expiration date

Exercise period or date

# of voting rights that may be acquired if the instrument is exercised

% of voting rights

Settlement

Merrill Lynch International

Right to Recall

262,775

0.40%

physical

Merrill Lynch International

Rights of Use

34,089

0.05%

physical

BofA Securities, Inc.

Right to Use

4,757,362

7.22%

physical

Bank of America, National Association

Swaps

15/10/2027

434

0.00%

cash

Bank of America, National Association

Swaps

15/06/2027

13,414

0.02%

cash

Bank of America, National Association

Swaps

30/06/2028

27

0.00%

cash

Bank of America, National Association

Swaps

31/07/2028

3,061

0.00%

cash

Merrill Lynch International

Swaps

15/01/2027

13,448

0.02%

cash

Merrill Lynch International

Swaps

30/04/2027

134,182

0.20%

cash

Merrill Lynch International

Swaps

30/06/2027

213

0.00%

cash

Merrill Lynch International

Swaps

15/06/2027

13,414

0.02%

cash

Merrill Lynch International

Swaps

09/09/2027

2,933

0.00%

cash

Merrill Lynch International

Swaps

29/01/2027

3,741

0.01%

cash

Merrill Lynch International

Swaps

31/03/2027

222

0.00%

cash

Merrill Lynch International

Swaps

30/09/2027

44

0.00%

cash

Merrill Lynch International

Swaps

26/02/2027

4,050

0.01%

cash

BofA Securities, Inc.

Swaps

30/09/2027

44

0.00%

cash

TOTAL

5,243,453

7.96%

TOTAL (A&B)

# of voting rights

% of voting rights

6,662,597

10.11%

The chain of control has been described at the end of the notification (section 11) and can be found here.

About Lakefront****® Biotherapeutics

Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:

Investor Relations Sherri Spear +1 412 522 6418 [email protected]